Results 101 to 110 of about 134,036 (314)

Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry

ESC Heart Failure, 2020
Aims In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication ...
Fernando deFrutos, Sonia Mirabet, Luis Ortega‐Paz, Irene Buera, Sara Darnés, Nuria Farré, Bernardo Perez, Raquel Adeliño, Ramón Bascompte, Jordi Pérez‐Rodón, Xavier Aparicio, Mario Sutil‐Vega, Adriana Soto, Mercedes Faraudo, Miguel Cainzos‐Achirica, Nicolás Manito   +15 more
doaj   +1 more source

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Interpretation of A Focus Shift From Sarcopenia to Muscle Health in the Asian Working Group for Sarcopenia 2025 Consensus Update

AGING MEDICINE, EarlyView.
The AWGS 2025 consensus shifts focus from diagnosing sarcopenia to promoting muscle health across the lifespan. It simplifies diagnosis to low muscle mass plus low strength, expands screening to middle‐aged adults, and integrates muscle health into the WHO ICOPE framework for early intervention and healthy aging.
Bi Jianghan, Li Jiaojiao, Kang Lin
wiley   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain‐of‐function pathogenic variants in the SMAD4 gene, a key player in TGF‐β signaling and a regulator of extracellular matrix homeostasis.
Alessandro De Falco, Alfonso Manuel D'Alessio, Nicola Brunetti‐Pierri   +2 more
wiley   +1 more source

Role of olmesartan in combination therapy in blood pressure control and vascular function

Vascular Health and Risk Management, 2010
Carlos M Ferrario, Ronald D SmithWake Forest University School of Medicine, Winston-Salem, North Carolina, USAAbstract: Angiotensin receptor blockers have emerged as a first-line therapy in the management of hypertension and hypertension-related ...
Carlos M Ferrario, Ronald D Smith
doaj  

Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. [PDF]

, 2017
BackgroundApproximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF).
Amurthur, Badri, Anand, Inder S, Ardell, Jeffrey L, DiCarlo, Lorenzo A, KenKnight, Bruce H, Kumar, H Uday, Libbus, Imad, Mittal, Sanjay, Premchand, Rajendra K   +8 more
core   +1 more source

Sex as a biological variable in nonclinical studies: Bridging scientific rigor, animal welfare, and regulatory expectations

Animal Models and Experimental Medicine, EarlyView.
Sex as a biological variable (SABV) is a critical determinant of pharmacokinetics, pharmacodynamics, and toxicity in nonclinical studies. This review highlights how inappropriate neglect of sex differences compromises animal welfare, scientific reproducibility, and regulatory compliance.
Kenta Onuma, Masaki Watanabe, Nobuya Sasaki   +2 more
wiley   +1 more source

Personalized medicine—a modern approach for the diagnosis and management of hypertension [PDF]

, 2017
The main goal of treating hypertension is to reduce blood pressure to physiological levels and thereby prevent risk of cardiovascular disease and hypertension-associated target organ damage.
Borghi, Claudio, Grassi, Guido, Rosei, Enrico Agabiti, Savoia, Carmine, Touyz, Rhian M., Volpe, Massimo   +5 more
core   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source